Research into outcomes from surgical intervention for intracranial aneurysms have focused on the clinical picture of the disease entity and death rate, comparison of different surgical methods, as well as the most common postoperative and postbleeding complications. From the nursing standpoint, the crucial element in assessing postoperative patients is the broadly understood functional outcome defining patients' ability to function in life, while at the same time recognising the impairments, in which patients will be dependent on the nursing staff. The aim of the study was to assess the functional outcomes of patients in the days following the surgical treatment. The research was carried out in Neurosurgical Department and Clinic, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland. A longitudinal study was carried out with 128 patients having undergone removal of an intracranial aneurysm. In the research both the observation and measuring scores were used. Also Hunt and Hess Grades, the Glasgow Coma Score and the Glasgow Outcome Score were used. To assess functional outcomes of patients, the Functional Capacity Scale was used. The research shows that the functional outcome improves with time, see Statistical analysis (p < 0.001). In the majority of patients some functional outcome deficit was observed mainly in the areas such as relieving oneself and maintaining personal hygiene. The conclusions from the research are as follows: (1) following the surgical treatment of the intracranial aneurysm (day 1, 3, 6 and 9) the majority of patients displayed considerable lack of functional outcome, and were therefore dependent on the nursing staff and relatives (family and friends); (2) on discharge (final measurement) patients were largely self-dependent and displayed negligible impairments of functional outcome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1471-6712.2008.00599.x | DOI Listing |
Background: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.
Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.
View Article and Find Full Text PDFBackground: Clinical trial sponsors rely on research sites to identify and enroll appropriate study participants and to correctly and reliably assess symptom severity and function over the course of the trial. Low-recruiting sites represent a large financial and operational burden and may negatively impact trial success either by selecting inappropriate participants and/or high prevalence of data quality issues. We previously reported that >60% of sites in schizophrenia clinical trials recruited ≤5 participants.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.
Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.
Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!